Clinical trials: sponsored by Canadian Cancer Trials Group
Non Small Cell Lung Cancer
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
The purpose of this study is to find out if giving reolysin in combination with docetaxel or pemetrexed can offer better results than standard therapy with docetaxel or pemetrexed alone.
- Trial name
- NCT01708993
- Testing
- Pemetrexed and Reolysin (and safety run-in), Pemetrexed, Docetaxel and Reolysin
- Where
- 12 sites in Canada
- Volunteers
- 166 people
- Sponsor
- Canadian Cancer Trials Group
Glioblastoma Multiforme
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
The standard or usual treatment for this disease is standard chemotherapy alone. AZD2014 is a new type of drug for glioblastoma multiforme. In the laboratory it has been shown to slow the growth of glioblastoma multiforme.
- Trial name
- NCT02619864
- Testing
- AZD2014
- Where
- 4 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Sarcoma
A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas
The purpose of this study is to find out what effects a new drug SB939 has on you and your sarcoma. This research is being done because there is a need for better treatment options for advanced or recurring sarcoma.
- Trial name
- IND200 (NCT01112384)
- Testing
- SB939
- Where
- 8 sites in Canada
- Volunteers
- 24 people
- Sponsor
- NCIC Clinical Trials Group
Metastatic Breast Cancer
Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
The purpose of this study is to find the highest dose of durvalumab that can be tolerated without causing very severe side effects when receiving standard treatment and to see what effects the study drug has on this type of…
- Trial name
- NCT02649686
- Testing
- Durvalumab, Trastuzumab
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Unspecified Adult Solid Tumor, Protocol Specific
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372736
- Testing
- AEG35156, docetaxel, protein expression analysis
- Where
- 3 sites in Canada
- Volunteers
- 27 people
- Sponsor
- NCIC Clinical Trials Group
Leukemia, Solid Tumours
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
This research is being done because SB939 has been shown to shrink tumours in animals and in some people and seems promising, but we are not sure if it can offer better results than standard treatment.
- Trial name
- NCT01184274
- Testing
- SB939
- Where
- 8 sites in Canada
- Volunteers
- 12 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
RATIONALE: Brivanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00640471
- Testing
- cetuximab, brivanib alaninate
- Where
- 37 sites in Canada
- Volunteers
- 750 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as flutamide and buserelin may stop the adrenal glands from producing androgens.
- Trial name
- NCT00054106
- Testing
- buserelin, custirsen sodium, flutamide
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- NCIC Clinical Trials Group
Endometrial Cancer
Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
RATIONALE: Ridaforolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00770185
- Testing
- ridaforolimus, gene expression analysis, immunohistochemistry staining method
- Where
- 11 sites in Canada
- Volunteers
- 35 people
- Sponsor
- NCIC Clinical Trials Group
Metastatic Colorectal Cancer
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
For the first phase of this study (phase I), the purpose will be to find the dose of a new drug, BKM120, that can safely be given in combination with standard dose panitumumab.
- Trial name
- NCT01591421
- Testing
- BKM120, Panitumumab
- Where
- 3 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well SB939 works in treating patients with recurrent or metastatic prostate…
- Trial name
- NCT01075308
- Testing
- HDAC inhibitor SB939
- Where
- 7 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Melanoma (Skin)
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
RATIONALE: Interleukin-21 may stimulate white blood cells, including natural killer cells, to kill melanoma cells. PURPOSE: This phase II trial is studying the side effects and how well interleukin-21 works in treating patients…
- Trial name
- NCT00514085
- Testing
- recombinant human interleukin-21, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 7 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to find out whether the new drug AT9283 will slow the growth of multiple myeloma. Side effects of AT9283 will also be closely monitored.
- Trial name
- NCT01145989
- Testing
- AT9283
- Where
- 6 sites in Canada
- Volunteers
- 8 people
- Sponsor
- NCIC Clinical Trials Group
Recurrent Lymphoma, Refractory Lymphoma
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.
- Conditions
- Recurrent Lymphoma, Refractory Lymphoma, Solid Tumours, Central Nervous System
- Trial name
- NCT02343718
- Testing
- Vinblastine, Temsirolimus
- Where
- 6 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Canadian Cancer Trials Group
Colorectal Cancer, Quality of Life
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00079066
- Testing
- cetuximab, quality-of-life assessment
- Where
- 33 sites in Australia, Canada
- Volunteers
- 572 people
- Sponsor
- NCIC Clinical Trials Group
Gynecologic Cancer
A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects it has on this type of cancer.
- Trial name
- NCT02459301
- Testing
- IPH2201
- Where
- 7 sites in Canada
- Volunteers
- 59 people
- Sponsor
- Canadian Cancer Trials Group
Leukemia, Myelodysplastic Syndromes
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer.
- Trial name
- NCT00516828
- Testing
- cytarabine
- Where
- 4 sites in Canada
- Volunteers
- 21 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as MK-0646, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00869752
- Testing
- anti-IGF-1R recombinant monoclonal antibody MK-0646, cisplatin, etoposide
- Where
- 3 sites in Canada
- Volunteers
- 12 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
RATIONALE: MET/VEGFR2 inhibitor Foretinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01068587
- Testing
- MET/VEGFR2 inhibitor Foretinib, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- 4 sites in Canada
- Volunteers
- 31 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: AZD2281 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00535353
- Testing
- irinotecan hydrochloride, olaparib
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- NCIC Clinical Trials Group